NY Post : Jay Z buys ‘Ace of Spades’ luxury Champagne label

Jay-Z has a few million reasons to toast.
The rap impresario has long been associated with Armand de Brignac — the Champagne known as “Ace of Spades,’’ due to its distinctive insignia — and now he owns it.
Or at least he owns an indeterminate chunk of the brand produced by Champagne Cattier, a French vintner since 1763, as details released on the deal on Wednesday were murky.

Jay-Z specifically bought the interest in Armand de Brignac held by Sovereign Brands, a New York-based wine and spirits company owned by the Berish family, after submitting an offer a Sovereign spokeswoman said “we simply couldn’t refuse.”
It was also an offer they wouldn’t divulge. Industry metrics, however, indicate the brand in its entirety is worth between $25 million and $30 million.
Jay-Z bio author Zack O’Malley Greenburg puts the wholesale price per Armand de Brignac bottle at $225.
Greenburg also suggests “Ace of Spades’’ generates annual revenue of $13.5 million and using an industry multiple of 2.1 times sales would make Armand de Brignac worth $28.3 million.
In his 2011 book, Greenburg estimates a production cost of $13 per bottle, which translates into a 94 percent profit margin.
Even a three-way split at the time among Cattier and Sovereign as co-owners and Jay-Z as unofficial hawker, the author notes, would deliver more than $4 million a year to each participant.

>>> Telecom Italia approached by private equity firms over joint offer for Oi

Telecom Italia approached by private equity firms over joint offer for Oi

Telecom Italia (TI) has been approached by two private equity firms over making a joint bid for Oi, the Brazilian phone operator, Italian language daily Il Sole 24 Ore reported. The unsourced report said that TI had been approached by Apax and Bain Capital over the matter.

The report said that the bid would take place via Tim Brasil, TI's mobile phone subsidiary in Brazil.

The report said that PT Portugal, Oi's Portuguese subsidiary, would be sold at a later date if the bid was successful. The report said that the sale of the Portuguese arm of Oi would help to keep down the amount of debt needed to carry out a takeover and make a successive merger with Tim Brasil easier to carry out.

The report said that TI would hold a 51% stake in the merged entity.

The report noted that Oi presently has a binding offer for PT Portugal from French cable group Altice valued at EUR 6.2bn. The report claimed that once Oi sells the asset it will use the funds to launch its own bid on Tim Brasil.


Source Il Sole 24 Ore

FT : AstraZeneca: priorities

AstraZeneca puts a lot of value on a stable dividend and earnings per share. Is that a good idea?

$4.20. This little number probably takes up quite a bit of space in the minds of executives at AstraZeneca. Azip, one of the company’s long-term incentive plans, is based on it. Azip awards are based on a four-year period from the beginning of 2013 to the end of 2016. The hurdles are simple: the dividend must not be cut, and earnings per share must not fall below 1.5 times the dividend. If either hurdle is missed during the period, the whole Azip award is forfeited. The award for Pascal Soriot, the company’s chief executive, is 89,960 shares, or £4.1m at the current price.
AstraZeneca’s dividend is $2.80; multiplying that by 1.5 makes $4.20. So, $4.20 is important. One should not exaggerate how important. Azip only represents 25 per cent of the long-term incentives for Mr Soriot. Still: £4.1m.
In 2013, AstraZeneca earned $5.05 per share. In its third-quarter earnings announcement on Thursday, the company said earnings would fall 15 per cent in 2014, in part because of the stronger dollar. That equates to $4.29.
If the company misses by a per cent or two, Mr Soriot’s £4.1m goes wherever incentive payments go when they do not go to executives. The company also gave a preview of 2015, saying that earnings would fall no lower.

Keeping earnings stable until the end of 2016 will not be easy. Most importantly, the acid reflux drug Nexium, which provides 14 per cent of revenue and probably an even larger slice of profits, may not keep its US patent protection.
The US Food and Drug Administration provided some help on Thursday when it withdrew its earlier support for generic Nexium from Ranbaxy, because that company’s plants were below standard. Other big products, such as Crestor and Seroquel, are in decline. But AstraZeneca’s pipeline, in oncology and diabetes especially, is very promising. That may well be enough.
A bigger question remains. Azip prioritises stability in the dividend and profits. If AstraZeneca aimed to be a defensive pharma investment, that would be fine. But after rejecting a rich offer from Pfizer, it has pinned its hopes on research and new products. Is that a good fit with Azip?

WWD : Estée Lauder on a Spree, Buys Frédéric Malle

In its third luxurious and somewhat idiosyncratic acquisition in less than a month, the Estée Lauder Cos. Inc. has signed an agreement to purchase artisinal fragrance brand Editions de Parfums Frédéric Malle.

The deal is expected to close in January. Terms were not disclosed, although Malle’s business is estimated at roughly $16 million wholesale.

The Malle acquisition joins new siblings Le Labo, an irreverent artisinal fragrance brand that Lauder acquired on Oct. 15, and upscale skin-care business Rodin Olio Lusso, which it bought last week.

Lauder appears to have entered into an acquisition battle with L’Oréal, which has snapped up Carol’s Daughter; NYX Cosmetics; Sayuki Custom Cosmetics; Brazil’s Niely Cosméticos; maker of Chinese facial masks Magic Holdings International Ltd.; Decléor, and Carita this year, although L’Oréal’s acquisitions seem to be larger and more expensive deals than Lauder’s.

Earlier this week, Fabrizio Freda, president and chief executive officer of Lauder, revealed to analysts that while first-quarter profits plunged 24.1 percent, the company’s brands are growing, and he doesn’t plan to sacrifice innovation. “We expect to generate sales growth of 5 to 6 percent this fiscal year, with a significant contribution coming from MAC and our midsize brands,” he told analysts. “To maintain our steady annual growth, we are driving our portfolio on two main fronts. We are strengthening and expanding our existing brands to keep them relevant in all our regions, and at the same time, we are actively seeking and nurturing the next generation with an eye to creating the next big brands of the future.”

Freda hinted to analysts that he might not be finished shopping yet: “We definitely are always scanning the market for future high-potential brands. We do this regularly.…We look at every single category,” he said, adding that when there is a “significant brand with meaningful ideas, we are interested.”

The purchases appear to indicate a change in course for Lauder’s fragrance business, which traditionally has concentrated on department store blockbuster scents. Malle and Le Labo are both high-end niche fragrance brands with similar pricing, albeit in slightly different segments. Malle’s ultraluxury scents retail in the $200 to nearly $400 range — a far cry from the Lauder brand’s stalwarts such as Beautiful, which can be had for less than $75. Both Malle and Le Labo have publicly opined that there are too many fragrances on the market, which runs contrary to the department store model of anniversarying fragrance launches with new introductions.

Le Labo, on the other hand, seems to cultivate its quirkiness: on its Web site, the founders proclaim, “We believe that we are only young once, but we can be immature forever.” It’s a bit of a different spin from Malle, who tends toward the elegant in his messaging.

Malle, seen by many as the godfather of the current artisinal fragrance movement, introduced the Editions de Parfums in 2000. The concept: the world’s best perfumers would compose exclusive, creative fragrances sold under their creator’s names — including Dominique Ropion and Edouard Fléchier — and chosen by Malle. His only restriction to perfumers: “Eliminate all that is superfluous or merely decorative.” He insists that each fragrance be designed to uniquely embrace the body of each wearer rather than just be a “pretty scent.”

The Le Labo team echoes a similar philosophy: “We believe that there are too many bottles of perfume and not enough soulful fragrances,” the company claims.

The Malle collection comprises 21 fragrances created by 12 master perfumers globally. In June, Malle opened his second New York store at 94 Greenwich Avenue in Manhattan’s West Village. He also has three stores in Paris, and noted that he envisions two or three more stores in the U.S., perhaps in Los Angeles and Miami, as well as a store in London.

Fragrance is in Malle’s blood: he is the grandson of Serge Heftler, the founder of Parfums Christian Dior, and Malle began his own career in 1986 with Roure Bertrand Dupont. Malle is the nephew of director Louis Malle.

Le Labo is said to generate yearly sales of $20 million to $30 million, and has roughly 24 fragrances, which retail from $140. It also does bath products and candles.

All three acquisitions also give Lauder some serious muscle in global luxury distribution. The brands are sold in prestigious doors such as Barneys New York, Colette in Paris, Milan’s 10 Corso Como and Liberty of London.

All the acquisitions will be overseen by John Demsey, group president for the Estée Lauder Cos., who also oversees the Lauder brand, MAC Cosmetics, Tom Ford, Jo Malone — another niche fragrance firm Lauder bought in the Nineties during its last acquisition binge — and other brands.

“Editions de Parfums Frédéric Malle represents the epitome of elegance,” said Freda. “Malle’s uncompromising dedication to pure perfumery has established him as the most sought-after collaborator by the world’s most talented perfumers. He has created a true luxury brand that augments our portfolio of prestige beautybeautybeauty products.”

Added Malle: “The Estée Lauder Cos. has great respect for the art of perfumery and for the creativity, dedication and mastery required to create truly exceptional fragrance experiences,” adding that it supports entrepreneurial concepts while preserving each brand’s unique attributes.

>>> Swisscom not planning Fastweb sale but would consider a sensational offer (t

Swisscom not planning Fastweb sale but would consider a sensational offer

Swisscom, the listed Swiss telco, would consider a sensational offer for its Italian unit Fastweb, Basler Zeitung reported. The Swiss daily cited Swisscom Chief Urs Schaeppi who said he would of course consider a sensational offer, but noted speculation of a sale crops up every year.

Fastweb achieved a turnover of EUR 1.23bn in the first 9 months of 2014.

Basler Zeitung

(BofA-ML) The Flow Show : $17.5bn Inflows into Equity Funds

* All Aboard: huge $17.5bn inflows into Equity funds this week, after $20bn last week...biggest 2 weeks of inflows since Oct’13; note SPX melt-up of 11.56% from 10/15 intraday lows

* The USS Bull: US accounts for lion’s share of equity inflows; Japan, Europe, China funds all record modest redemptions despite BoJ QQE & prospective easing in Europe/China

* IG Rules: another week of big inflows to IG bond funds ($4.9bn); Chart 1 shows IG funds a 2014 winner, bested only by inflows to long-term govt bonds

* Inflation capitulation continues: outflows for TIPs, Floating Rate & Gold funds...the other big flow trend of 2014

* Growth>Value: by sector, chunky outflows from materials ($0.8bn) & real estate ($0.4bn); inflows to tech ($0.6bn) and healthcare ($0.5bn)

>>> Asset Class Flows
* Equities: $17.5bn inflows ($19bn inflows to ETF’s – SPY, QQQ, IWM)
* Bonds: $9.0bn inflows (7 straight weeks) (Table 1)
* Precious metals: $0.6bn outflows (outflows in 10 out of past 11 weeks)

>>> Equity Flows
* Europe: $0.5bn outflows (outflows in 9 out of past 10 weeks) (Table 2)
* Japan: modest $0.4 outflows
* US: $15.3bn inflows (all via ETF’s)
* EM: flat; but note Chinese equity funds see 8th straight week of redemptions ($0.4bn)

>>> Fixed Income Flows
* 46 straight weeks of inflows to IG bond funds ($4.9bn) (Chart 2)
* 3 straight weeks of inflows to HY bond funds ($3.2bn)
* $0.8bn inflows to EM debt funds (largest in 14 weeks)
* 17 straight weeks of outflows from bank loan funds ($0.4bn)
* 9 straight weeks of outflows from TIPS ($0.1bn)

>>> What to look at today - 7th of November 2014

US Market Closed Higher ahead of October NFPM , USD Stronger after ECB Comments, weighted on Crude again ($77.9) but Energy sector closed higher, cyclical sectors, consumer discretionary (+0.9%) and materials (+0.8%) displayed strength while financials (+0.1%) and technology (-0.1%) lagged, Rangold (+9.2%) numbers boosted the materials sector...volume were ahead @ 730mil shares...VIX @ 13.67 -3.53% ...US after Hours NAME +33.2%, ECOM +29.1%, ZNGA +6.4%, SLXP -37.3%,
PFMT -17.9% following earnings/guidance...Cleveland Fed President Mester unfurled her relatively hawkish stance at a speech in NYU, noting she would have liked for the "considerable time" language to be taken out of the FOMC statement. Mester added she would prefer not to wait until price objectives are reached before adjusting policy, stating 2% inflation would return by the end of 2016 and unemployment of 5.5% would be achieved next year. In the long run, Mester sees the Fed funds rate around 3.75%, which is notably below the 5.25% pre-GFC peak...USD/JPY briefly dipped lower by about 25pips after more neutral comments from Econ Min Amari calling both excessive rises AND falls in JPY as undesirable. Subsequently, Fin Min Aso took a more favorable stance on the issue, noting weak Yen's positive impact toward exports and the progress BOJ is making toward stopping deflation with extra easing measures. USD/JPY continued its upward push, approaching overnight 7-year high around 115.50...Nikkei +0.52% Hang Seng -0.32% Shanghai -0.44%

Eur$ 1.2379 S&P +0.22% EurosToxx +0.42% DAX +0.49% FTSE +0.33% SMI +0.29%

Macro
- S&P’s Kraemer Says ‘Writing of QE Is on the Wall’ for Europe {NSN NEN9CB6K50YX <go>}
- China Oct. Retail Auto Sales Rise 9.3% on Year, PCA Says
- Switzerland SA Oct. Unemployment Rate 3.2%; Est. 3.2%
- Soros Says Euro Faces Political Crisis, Le Figaro Reports
- OPEC May Pare Oil Production Amid Oil Price Below $70/Barrel:WSJ
- France to Seize Assets of Corrupt China Officials: Daily Link
- Europe Telcos Want EU Regulation of Facebook, Google: Rheinische
- Economy Minister Gabriel Plans Industry Alliance: Handelsblatt

Keep an eye on :
- AIR FP : Airbus Said to Reach Deal With Atlasjet for $3b Order: Reuters
- AKER NO : Aker Solutions 3Q Net NOK265m vs Est. NOK299m; Backlog NOK49b
- ALV GY : Allianz 3Q Net EU1.61 Bln Vs Est. EU1.57 Bln
- ANA SM : Acciona 9M Net EU149M Vs EU75M a Year Earlier
- MT NA : ArcelorMittal 3Q Ebitda Beats, Reiterates FY Ebitda Forecast
- ATO FP : Atos Closes New Credit Line; Delisting of Bull Planned, CFO Says
- CS FP : Axa Sells Unit in Hong Kong to Principal Financial Group
- BULL FP : Bull 3Q LFL Revenues Fall 5.3% on Weak Activity in France
- ELUX SS : AB Electrolux Cut to BBB From BBB+ by S&P, Outlook Stable
- ENE SM : Enel Sets Price for Endesa Retail Offer at Max. EU15.535/shr
- FNTN GY : Freenet 3Q Ebitda Climbs 4% to EU96.3 M
- EUCA GY : Euromicron 9M Sales Up 6%, Net Down 44%; Confirms 2014 Forecast
- DEC FP : VTB May Sell Stake in Outdoor Advertising Operator: Kommersant
- MOR GY : MorphoSys 3Q Rev. Up, Keeps FY Forecast; Fast-Track for MOR208
- PAL AV : Palfinger 9M Profit Net; Sees Lower Earnings on Slack Demand
- PUB FP : Sapient 3Q Adj. EPS Meets, Service Rev. Misses Ests.
- CFR VX : Richemont 1H Net Misses Ests., Oct. Sales Down 1% Constant FX, Says Cost Controls Have Been Put Into Place
- SKAB SS : Skanska 3Q Op. Profit, Revenue Beat Est.
- SREN VX : Swiss Re 3Q Net Income Beats Ests; Proposes 2 New Board Members
- TIT IM : Telecom Italia 3Q Sales Beat; Mobile Service Rev. Improves
- TKA AV : Telekom Austria to Sell Up to EU1b in New Shares
- UCB BB : UCB Adjusts 2014 Forecasts After U.S. Kremers Unit Sale
- MF FP : Wendel Says Well Placed to Meet Its 2013-2017 Objectives

>>> Brokers Upgrades & Downgrades - 7th of November 2014

>>> Up
*BARRY CALLEBAUT RAISED TO HOLD VS SELL AT BERENBERG
*CREDIT SUISSE RAISED TO HOLD FROM SELL AT BANKHAUS LAMPE
*EXPERIAN RAISED TO NEUTRAL VS SELL AT GOLDMAN
*GEM DIAMONDS RAISED TO MARKET PERFORM VS UNDERPERFORM AT BMO
*INDRA RAISED TO NEUTRAL VS SELL AT UBS
*INTERTEK RAISED TO BUY AT GOLDMAN
*ROVI RAISED TO BUY VS NEUTRAL AT UBS
*SCHRODERS RAISED TO BUY VS NEUTRAL AT UBS
*SNAM RAISED TO NEUTRAL AT GOLDMAN

>>> Down
*ADECCO CUT TO NEUTRAL VS BUY AT GOLDMAN
*HIKMA CUT TO NEUTRAL VS BUY AT GOLDMAN
*MICHAEL PAGE CUT TO NEUTRAL VS BUY AT GOLDMAN
*O'KEY CUT TO UNDERWEIGHT VS NEUTRAL AT HSBC
*RANDSTAD CUT TO NEUTRAL VS BUY AT GOLDMAN
*RSA INSURANCE CUT TO SELL VS HOLD AT CANACCORD; PT GBP 440

>>> PT changes


>>> Initiation
*B&M RATED NEW BUY AT CITI, PT 310P
*BPOST RESUMED BUY AT GOLDMAN
*CTT CORREIOS DE PORTUGAL RATED NEW SELL AT GOLDMAN
*DEUTSCHE POST RESUMED NEUTRAL AT GOLDMAN
*INFINIS ENERGY RATED NEW OVERWEIGHT AT BARCLAYS, PT 275P
*POUNDLAND RATED NEW BUY AT CITI, PT 350P
*ROYAL MAIL RESUMED BUY AT GOLDMAN
*TNT EXPRESS RESUMED NEUTRAL AT GOLDMAN

>>> Call
>> Stock
*HAYS EXITS GOLDMAN CONVICTION BUY LIST, STAYS BUY

(BFW) S&P’s Kraemer Says ‘Writing of QE Is on the Wall’ for Europe


S&P’s Kraemer Says ‘Writing of QE Is on the Wall’ for Europe
2014-11-07 00:57:47.652 GMT


By Colin Keatinge
Nov. 7 (Bloomberg) -- Many imbalances in Europe that need
to be addressed, Standard & Poor’s Head of Sovereign Ratings
Moritz Kraemer says in interview with Bloomberg TV today.
* Low rates created “sense of complacency,” he says
* Sees problems in Europe compared to Japan because of
difficulty of coordinating between govts in Europe
* ECB action allows Europe govts to continue “dithering,” he
says
* Says negative outlooks watched closely are France, Italy


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Colin Keatinge in Singapore at +65-6231-3479 or
ckeatinge@bloomberg.net
To contact the editors responsible for this story:
Grant Clark at +65-6212-1101 or
gclark@bloomberg.net
Colin Keatinge